Showing 683 results
-
Media Release /PARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks1; no…
-
Media Release /
-
Media Release /Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164…
-
Media Release /
-
Media Release /Podcast to feature 1:1 interviews conducted by Lauper with patients and advocates to address the impact psoriasis (PsO) can have on day-to-day life Guests to include real patient advocates and…
-
Media Release /
-
Media Release /Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
-
Media Release /
-
Media Release /If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and…
-
Media Release /
